Company / Gross Profit
Amphstar Pharmaceuticals, Inc. Gross Profit History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$356.1M
FY2025
5-year range
$199.7M / $373.9M
FY2021-FY2025
Trend
-4.8%
vs FY2024
Sector context
#17 of 29
Health Care
What the data says
At $356M, Amphstar Pharmaceuticals, Inc.'s gross profit ranks #17 of 29 in the Health Care sector.
Based on SEC 10-K filings.
$356M in FY2025 with a 5-year CAGR of +20.0%.
Remained stable around $356M over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +12.7%
- 5-Year CAGR
- +20.0%
- 10-Year CAGR
- -
Sector benchmark
#17 of 29 in Health CareTop 59% of 29This company $356.1M Sector average $3.5B
▼
-89.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +20.0%, indicating consistent growth.
- In FY2025, gross profit decreased 4.8% year-over-year.
- Ranks #17 out of 29 companies in the Health Care sector.
- Peak gross profit was recorded in FY2024.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $356.1M | -4.8% |
| FY2024 | $373.9M | +6.5% |
| FY2023 | $351.1M | +41.1% |
| FY2022 | $248.9M | +24.6% |
| FY2021 | $199.7M | +39.3% |
| FY2020 | $143.3M | +8.7% |
| FY2019 | $131.9M | +23.3% |
| FY2018 | $107.0M | +18.2% |
| FY2017 | $90.5M | -13.1% |
| FY2016 | $104.2M | +34.7% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026